Page 55 - 《南京医科大学学报（自然科学版）》2026年第3期
P. 55

第46卷第3期               焦   艺，赵廷昱，刘凌翔. 胸腺上皮肿瘤免疫治疗进展与不良事件管理［J］.
                  2026年3月                    南京医科大学学报（自然科学版），2026，46（3）：355-365，374                     ·363 ·


                   Author’s Contributions：                             a multicentre，single⁃arm，phase 2 trial［J］. Lancet Oncol，
                   JIAO Yi was responsible for the writing and editing of original  2025，26（3）：331-342
                draft. ZHAO Tingyu was responsible for the writing of original  ［12］GIACCONE G，KIM C. Durable response in patients with
                draft. LIU Lingxiang was responsible for conceptualization and  thymic carcinoma treated with pembrolizumab after
                supervision.                                           prolonged follow⁃up［J］. J Thorac Oncol，2021，16（3）：
               ［参考文献］                                                  483-485
                                                                 ［13］MANIAR R，LOEHRER P J Sr. Understanding the land⁃
               ［1］ RIOJA P，RUIZ R，GALVEZ⁃NINO M，et al.Epidemiology
                                                                       scape of immunotherapy in thymic epithelial tumors［J］.
                    of thymic epithelial tumors：22 ⁃ years experience from a
                                                                       Cancer，2023，129（8）：1162-1172
                    single⁃institution［J］. Thorac Cancer，2021，12（4）：420-
                                                                 ［14］WANG W X，LIN G，HAO Y，et al. Treatment outcomes
                    425
                                                                       and prognosis of immune checkpoint inhibitors therapy in
               ［2］ MARX A，CHAN J K C，CHALABREYSSE L，et al. The
                                                                       patients with advanced thymic carcinoma：a multicentre
                    2021 WHO classification of tumors of the thymus and
                                                                       retrospective study［J］. Eur J Cancer，2022，174：21-30
                    mediastinum：what is new in thymic epithelial，germ cell，
                                                                 ［15］ALAM S M，TRAVERS P J，WUNG J L，et al. T⁃cell⁃
                    and mesenchymal tumors?［J］. J Thorac Oncol，2022，17
                                                                       receptor affinity and thymocyte positive selection［J］.
                    （2）：200-213
                                                                       Nature，1996，381（6583）：616-620
               ［3］ TARTARONE A，LEROSE R，LETTINI A R，et al. Current
                                                                 ［16］ STARR T K，JAMESON S C，HOGQUIST K A. Positive
                    treatment approaches for thymic epithelial tumors［J］. Life  and negative selection of T cells［J］. Annu Rev Immunol，
                    （Basel），2023，13（5）：1170
                                                                       2003，21：139-176
               ［4］ BERGHMANS T，DURIEUX V，HOLBRECHTS S，et al.
                                                                 ［17］ IRLA M. Instructive cues of thymic T cell selection［J］.
                    Systemic treatments for thymoma and thymic carcinoma：
                                                                       Annu Rev Immunol，2022，40：95-119
                    a systematic review［J］. Lung Cancer，2018，126：25-31  ［18］MCDONALD B D，BUNKER J J，ERICKSON S A，et al.
               ［5］ ZUCALI P A，DE PAS T，PALMIERI G，et al. PhaseⅡ
                                                                       Crossreactive αβ T cell receptors are the predominant
                    study of everolimus in patients with thymoma and thymic  targets of thymocyte negative selection［J］. Immunity，
                    carcinoma previously treated with cisplatin⁃based chemo⁃
                                                                       2015，43（5）：859-869
                    therapy［J］. J Clin Oncol，2018，36（4）：342-349  ［19］SURH C D，SPRENT J. T⁃cell apoptosis detected in situ
               ［6］ THOMAS A，RAJAN A，BERMAN A，et al. Sunitinib in
                                                                       during positive and negative selection in the thymus［J］.
                    patients with chemotherapy ⁃ refractory thymoma and  Nature，1994，372（6501）：100-103
                    thymic carcinoma：an open⁃label phase 2 trial［J］. Lancet  ［20］ASHBY K M，HOGQUIST K A. Author correction：a guide
                    Oncol，2015，16（2）：177-186                           to thymic selection of T cells［J］. Nat Rev Immunol，
               ［7］ GIACCONE G，KIM C，THOMPSON J，et al. Pembroli⁃        2023，23（10）：697
                     zumab in patients with thymic carcinoma：a single⁃arm，  ［21］SHINZAWA M，MOSEMAN E A，GOSSA S，et al. Reversal
                     single⁃centre，phase 2 study［J］. Lancet Oncol，2018，19  of the T cell immune system reveals the molecular basis
                    （3）：347-355                                        for T cell lineage fate determination in the thymus［J］.
               ［8］ CHO J，KIM H S，KU B M，et al. Pembrolizumab for       Nat Immunol，2022，23（5）：731-742
                    patients with refractory or relapsed thymic epithelial  ［22］NITTA T，MURATA S，UENO T，et al. Thymic microenvi⁃
                    tumor：an open ⁃ label phase Ⅱ trial［J］. J Clin Oncol，  ronments for T⁃cell repertoire formation［J］. Adv Immunol，
                    2019，37（24）：2162-2170                              2008，99：59-94
               ［9］ KATSUYA Y，HORINOUCHI H，SETO T，et al. Single⁃arm，  ［23］ HU Z C，LANCASTER J N，SASIPONGANAN C，et al.
                    multicentre，phaseⅡtrial of nivolumab for unresectable or  CCR4 promotes medullary entry and thymocyte⁃dendritic
                    recurrent thymic carcinoma：PRIMER study［J］. Eur J  cell interactions required for central tolerance［J］. J Exp
                    Cancer，2019，113：78-86                              Med，2015，212（11）：1947-1965
               ［10］ZHAO C，RAJAN A. Immune checkpoint inhibitors for  ［24］PUNT J A，OSBORNE B A，TAKAHAMA Y，et al. Nega⁃
                                                                                      +
                    treatment of thymic epithelial tumors：how to maximize  tive selection of CD4 CD8 thymocytes by T cell receptor⁃
                                                                                         +
                    benefit and optimize risk?［J］. Mediastinum，2019，3：35  induced apoptosis requires a costimulatory signal that can
               ［11］ SHUKUYA T，ASAO T，GOTO Y，et al. Activity and safety  be provided by CD28［J］. J Exp Med，1994，179（2）：709-
                    of atezolizumab plus carboplatin and paclitaxel in patients  713
                    with advanced or recurrent thymic carcinoma（MARBLE）：  ［25］BREED E R，WATANABE M，HOGQUIST K A. Measuring
   50   51   52   53   54   55   56   57   58   59   60